{"id":"NCT00604383","sponsor":"Chromaderm, Inc.","briefTitle":"Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study","officialTitle":"Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-03","primaryCompletion":"2005-06","completion":"2005-06","firstPosted":"2008-01-30","resultsPosted":"2016-01-28","lastUpdate":"2016-10-06"},"enrollment":685,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Retinopathy"],"interventions":[{"type":"DRUG","name":"ruboxistaurin","otherNames":["LY333531"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Ruboxistaurin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.","primaryOutcome":{"measure":"Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of â‰¥15 Letters Measured Twice During a 6-month Period","timeFrame":"Baseline through 36 months","effectByArm":[{"arm":"Ruboxistaurin","deltaMin":5.5,"sd":null},{"arm":"Placebo","deltaMin":9.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.034"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["18708615"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":145,"n":345},"commonTop":["Oedema peripheral","Nasopharyngitis","Hypertension","Cough","Influenza"]}}